jili 187

jili 187 zkMe Network Celebrates Second Anniversary, Announces Strategic Ecosystem Rewards Program for 2025LAUSANNE , Switzerland , Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 34,900 of the Company's common shares to three new employees on December 2, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland , and has operations in London and New Jersey . For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn . ZYNLONTA ® is a registered trademark of ADC Therapeutics SA. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA ® revenue in the United States ; the ability of our partners to commercialize ZYNLONTA ® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA ® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS: Investors Marcy Graham ADC Therapeutics Marcy.Graham@adctherapeutics.com +1 650-667-6450 Media Nicole Riley ADC Therapeutics Nicole.Riley@adctherapeutics.com +1 862-926-9040 View original content to download multimedia: https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302320100.html SOURCE ADC Therapeutics SA

After-hours movers: Oracle, MongoDB, C3 AI, Lilly and more

Jessica Alba and Tracey Nyberg’s Lady Metalmark Entertainment has boarded “Queens,” Switzerland’s official selection for the international feature Oscar, as executive producer. The film follows two teenage sisters living in Peru in 1992 as the country slides into political unrest. They are about to leave with their mother to live in the U.S. but they need their father to sign consent papers — he’s been absent for years but now he decides to win back his two “queens.” Abril Gjurinovic, Luana Vega and Jimena Lindo star. The film won the Audience Award at this year’s Locarno Film Festival and the Grand Prix in Generation Kplus at the Berlinale, after world premiering at the Sundance Film Festival. Reynicke, who co-wrote the screenplay with Diego Vega Vidal, drew on her own experience of leaving Peru as a young girl during a period of political turmoil in the early 1990s. She now lives in Switzerland, and the film is a Swiss-Peruvian co-production. The films is a great fit for actor, producer and businesswoman Alba (she founded the Honest Company). Her shingle Lady Metalmark Entertainment is committed to work with diverse artists and to champion female-driven, culturally diverse and Latino inspired stories. “We are honored to join Klaudia Reynicke’s extraordinary film ‘Queens’ as executive producers,” said Alba and Nyberg in a joint statement. “This powerful story illuminates the unshakable strength of a mother’s love and her relentless drive to create a better future for her children. Capturing stellar performances amidst the rugged beauty of Lima, Peru, Klaudia is a filmmaker of exceptional talent — something we are excited for audiences to discover as they laugh and cry alongside Elena and her daughters, with a story that will resonate long after the credits roll.” “In ‘Queens,’ I wanted to craft a film that was both personal and universal, a story about sisterhood, identity, migration and love,” said Reynicke. “Jessica Alba understands these themes on an emotional level, which is why having her as an executive producer feels like a dream. With her passion and heritage guiding the film, Queens becomes more than just a story, it’s a tribute to the strength of families and the hope that carries us forward. I am equally thrilled that her partner, Tracey Nyberg, is joining us as an executive producer, bringing her expertise and dedication to amplify the impact of this story. This collaboration is a testament to the power of women supporting each other to tell stories that matter — stories about childhood, parenthood, resilience, and the strength we find in hope.”

Bill Belichick, the former NFL head coach who led the New England Patriots to six Super Bowl wins, will be the new head coach of the University of North Carolina's football program. The school announced the news on social media Wednesday night. He's agreed to a five-year deal with the Tar Heels, which is pending approval from the university's board of trustees and board of governors. A press conference was held at the school on Thursday to formally announce Belichick as the new head coach, which he described as a dream come true. UNC Chancellor Lee H. Roberts and Director of Athletics Bubba Cunningham jokingly gifted Belichick a Tar Heels sweatshirt with his trademark short sleeves. RELATED STORY | Bill Belichick 'moves on' from coaching New England Patriots "I grew up in college football with my dad," Belichick said, showing off one of his father's old sweatshirts from when he was an assistant coach at the school for a couple of years before he went on to coach at the U.S. Naval Academy for over three decades. He said Carolina was home and his family always joked when he was growing up that his first words were "beat Duke" — the Tar Heels' rival school. Belichick won two Super Bowls with the New York Giants before continuing his career with the Cleveland Browns and New York Jets. But he's known for his career with the Patriots, where he was the head coach for 24 seasons and won 13 AFC championship titles and made nine Super Bowl appearances. He retired from the NFL as the second-winningest coach in NFL history.